Termider

Quick links to important sections

Termider

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Termider

Quick Facts

Property Description
Active Ingredient Terbinafine Hydrochloride
Pharmacological Class Allylamine Antifungal Agent
Origin / Type Synthetic Naphthalene Derivative
Dosage Forms Oral Tablets, Topical Preparations (Cream, Gel, Solution)
Primary Action Fungicidal (eliminates fungal cells)

What Type of Medicine is Termider (Terbinafine)?

Termider is a medicinal product containing the active ingredient Terbinafine Hydrochloride, and it is formally classified as an allylamine antifungal agent. The compound itself is a synthetic naphthalene derivative engineered for highly targeted action against fungal pathogens. This designation places it within a pharmacological class known for its primary fungicidal effect, a property that is clinically recognized for its efficacy against dermatophytes, which cause common skin infections. This fungicidal property ensures the medicine is designed to eliminate the fungal cells rather than merely suppress their growth, which is characteristic of fungistatic agents.

Composition and Available Forms of Termider

The composition of Termider centers on the single active ingredient, Terbinafine Hydrochloride, which is formulated with an appropriate inert pharmaceutical base depending on the intended route of administration. The medicine is available for both systemic and topical use, primarily manufactured as oral tablets and various topical preparations, which include cream, gel, solution, and spray formulations. The versatility of these dosage forms ensures the fungicidal agent can be delivered effectively to treat both superficial skin infections and those affecting deeper tissues. Pharmacological studies have supported the compound's ability to concentrate in the skin, nails, and fatty tissues, a feature that enhances its effectiveness in these target areas.

The General Purpose of This Fungicidal Agent

The general purpose of Termider is to provide targeted elimination of the fungal organisms responsible for a broad spectrum of mycoses. This function is achieved by the drug acting as a squalene epoxidase inhibitor, a key mechanism that blocks the fungal cell's ability to produce essential ergosterol while simultaneously causing the toxic accumulation of squalene within the cell. The primary benefit of this potent allylamine agent is the definitive clearance of the fungal pathogen at a cellular level, resolving the source of the infection. A typical use scenario involves targeting the mycoses that affect the skin or nails.

What side effects are possible with Termider?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse reactions of Termider (Terbinafine) based on their frequency and the body system affected. These classifications structure the medicine’s safety profile, ranging from very common events to rare, serious adverse reactions.

Frequency-Classified Adverse Reactions

The most frequently documented events, classified as Very Common by regulatory authorities (occurring in ge 1 out of 10 patients), typically involve the gastrointestinal system (e.g., fullness, dyspepsia, decreased appetite), the skin (rash, urticaria), and the musculoskeletal system (arthralgia and myalgia). Reactions listed as Common include nausea, diarrhea, abdominal pain, headache, and disturbances to taste (dysgeusia).

System-Specific and Serious Safety Events

The official label documents rare, but clinically significant, safety risks primarily concerning the Hepato-biliary System and Blood and Lymphatic System. Rare cases of severe hepatic dysfunction, including liver failure, have been reported. Very rare, but serious, effects include severe dermatological reactions like Stevens-Johnson syndrome, blood dyscrasias (e.g., neutropenia), and Thrombotic Microangiopathy.

Safety Constraints and Special Populations

Use of the medicine is officially constrained by certain pre-existing conditions. Termider is contraindicated (should not be used) in individuals with active or chronic liver disease. Use is also not recommended in patients with severe renal impairment. Regulatory documents specify that taste and smell disturbances (dysgeusia, anosmia) may be prolonged or, in some cases, permanent, and they advise pre-treatment measurement of serum transaminases (ALT and AST) to establish baseline liver function.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations: The official labeling states that acute overexposure to Termider is primarily characterized by gastrointestinal and central nervous system disturbances. Documented manifestations include nausea, vomiting, abdominal pain, dizziness, headache, rash, and frequent urination (pollakiuria).

Physiological systems affected (as stated in label): Gastrointestinal, Central Nervous System, and Dermatologic systems are noted to be affected by overdose.

Dose-related or exposure-related factors (if applicable): Acute ingestion of large doses, such as those up to five grams, has been observed, with a risk for severe gastrointestinal symptoms associated with very high intake.

Population-specific overdose notes (if applicable): No specific population-based risk factors are explicitly listed in the general overdose sections of official regulatory documents.

Emergency-response statements (as written in official documents): Treatment should focus on the elimination of the drug, often by administering activated charcoal. Symptomatic and supportive therapy should be administered, and clinical status monitoring may be required.

When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention for a known or suspected overdose, or contact emergency services immediately.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The severity is generally related to the extent of gastrointestinal and central nervous system symptoms; no specific antidote is known.

Regulatory basis (EMA / FDA / etc.): Information is based on FDA Prescribing Information and Summary of Product Characteristics (SmPC) data.

Overdose-context constraints (as defined in official documents): No specific antidote is known for Termider (terbinafine) overdose.


Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with a cluster of symptoms including nausea, vomiting, abdominal pain, and headache.
  • No specific antidote is known for Termider, confirming the necessity of symptomatic and supportive therapy.
  • The regulatory mandate is to seek immediate medical attention or contact emergency services for any suspected overdose.

Connection to the overall overdose profile (3 sentences): Official regulatory documents define the overdose profile primarily by expected gastrointestinal and central nervous system manifestations, such as vomiting and headache. The lack of a specific antidote necessitates that the emergency-seeking condition is defined by the official mandate to seek immediate medical attention. Management procedures are officially restricted to symptomatic and supportive treatment, including the use of activated charcoal to facilitate drug elimination.

Therapeutic Uses of Termider

What Termider Treats: Main Uses and Benefits

Termider is applicable across domains where additional symptomatic support is needed, and is relevant for easing symptom clusters that may become intense or disruptive. This type of medication is commonly used to help with symptomatic relief in situations where patients experience issues such as itching, burning, cracking, and scaling associated with acute episodes.


Easing Acute Symptomatic Discomfort

This medication is relevant in contexts marked by increased discomfort or tension, and may be part of symptomatic management for symptoms related to physical discomfort that create noticeable physiological strain. It contributes to easing the overall symptom load during difficult episodes and may assist with maintaining functional stability.


Supporting Episodic and Fluctuating Symptom Patterns

Termider is commonly used across conditions presenting with acute or recurrent episodes or conditions involving episodic or fluctuating manifestations. It offers symptomatic relief that helps patients cope more steadily when symptoms are more noticeable. It is considered relevant in clinical settings that involve temporary discomfort, systemic imbalance, and irritative states.


Addressing Symptom Clusters Leading to Functional Strain

The medication may be applied in addressing symptom clusters that appear suddenly or fluctuate, particularly in situations where symptoms lead to temporary functional strain. It contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Noticeable Physiological Strain

Regulatory References

  1. US National Library of Medicine (DailyMed)

Eligibility and Restrictions for Use

Who Can and Cannot Use Termider? Official Regulatory Eligibility

The eligibility for using oral Termider (Terbinafine) is strictly defined by regulatory labeling based on patient health status, organ function, and age.

Absolute Contraindications

Oral Termider is strictly contraindicated (must not be used) in two primary populations: patients with chronic or active liver disease and individuals with a documented history of allergic reaction or hypersensitivity to terbinafine.

Restricted and Conditional Use

Use is not recommended in patients with impaired renal function (creatinine clearance leq 50 mL/min), as safety in this population has not been adequately established. Similarly, use is not recommended during pregnancy or lactation because the substance is excreted into human milk and clinical data are limited.

Age-Group Eligibility

The medicine is established for use in adults. For the pediatric population, the safety and efficacy of the oral tablets for onychomycosis have not been established. Use is only established for specific formulations (oral granules) in children four years of age and older for certain conditions. Geriatric patients are eligible, but use requires caution due to the potential for underlying organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Termider is primarily defined by its pharmacokinetic effects, specifically its influence on metabolic enzymes and clearance pathways.

Interaction Scope Official Regulatory Statement
Mechanistic Basis Termider is documented as an inhibitor of the CYP450 2D6 (CYP2D6) isozyme. Termider is extensively metabolized by CYP isoenzymes, including CYP2C9, CYP1A2, and CYP3A4.
Interaction Restriction Termider tablets are contraindicated in patients with chronic or active hepatic disease.
Population Notes In patients with renal impairment (creatinine clearance le 50 mL/min), Termider clearance is documented to be decreased by approximately 50%.

Official Interaction Statements:

  • Co-administration with the CYP2D6 substrate Desipramine results in a 5-fold increase in the Area Under the Curve (AUC) of Desipramine.
  • The CYP inducer Rifampin is documented to increase Termider clearance by 100%.
  • The CYP inhibitor Cimetidine is documented to decrease Termider clearance by 33%.
  • Fluconazole (a CYP inhibitor) co-administration causes a 69% increase in Termider AUC.
  • Food co-administration is associated with an increase in Termider AUC of less than 20%.

Connection to the overall interaction profile: Regulatory documents define this product's interaction structure based on its potent CYP2D6 inhibition and its susceptibility to other CYP-modifying agents, which results in significant and quantified changes in exposure for both Termider and co-administered substances. The profile includes mandatory condition-based restrictions, such as the contraindication in chronic or active liver disease.

Mechanism of Action

Molecular Blockade of Fungal Ergosterol Synthesis

Termider's primary interaction is the selective inhibition of the fungal enzyme Squalene Epoxidase (SQLE). This precise molecular blockade halts the ergosterol biosynthesis pathway, preventing the fungal pathogen from producing the essential sterol needed for cell membrane integrity. The mechanism is highly selective, as it targets an enzyme structurally distinct from mammalian cholesterol synthesis enzymes.


Dual-Action Fungicidal Cascade

The enzymatic inhibition triggers a dual lethal cascade within the fungal cell: the critical depletion of ergosterol and the toxic accumulation of squalene. This combined failure of structural components and internal toxicity causes the rapid lysis and death of the fungal cell, defining the drug's fungicidal physiological effect.


Sustained Action in Keratinous Tissues

The drug's intrinsic lipophilicity drives its accumulation in high concentrations within the skin, nails, and hair follicles, creating a localized reservoir. This distribution mechanism ensures the destructive fungicidal action persists for an extended period within the keratinous tissues, contributing to a prolonged persistence of the mechanism in these tissues.

Dosage and Administration Information

How Termider is Used

Termider, which contains Terbinafine, is administered through two main routes: oral (systemic) and topical (cutaneous), determined by the site and extent of the fungal infection. The primary oral dosage for adults is 250 mg once daily for all approved indications, taken preferably at the same time each day.


Oral and Topical Administration Principles

Feature Official Guideline
Route of Administration Oral (Tablets/Granules) and Topical (Cream, Gel, or Solution).
Timing in Relation to Meals Oral tablets may be taken with or without food. Oral granules, when used, must be mixed with soft, non-acidic food and swallowed unchewed.
Dosing Frequency Once daily for oral tablets. Once to twice daily for topical applications.
Treatment Duration The total length of the course is fixed and varies by site: 6 weeks for fingernail onychomycosis and 12 weeks for toenail onychomycosis. Topical treatment is typically limited to 1 to 4 weeks.

Usage Constraints and Adjustments

Dosage for pediatric patients is weight-based, ranging from 125 mg to 250 mg once daily, with the oral granule formulation often used for proper administration in this population. The oral form of Termider is officially not recommended in individuals diagnosed with chronic or active liver disease or those with severely reduced kidney function (creatinine clearance le 50 mL/ min).

If a dose of the oral tablet is missed, it should be taken as soon as the lapse is noticed. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued; two doses must not be taken together.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Termider

This section provides an overview of the official research evidence for Termider (Terbinafine) to help contextualize what has been studied and what is currently known according to authoritative sources. The research explores outcomes related to physical discomfort and functional imbalance associated with fungal infections, but findings describe group patterns, not personal outcomes.


Evidence for Use in Fungal Nail Infection (Onychomycosis)

Research exploring outcomes related to fungal infections of the nails has primarily utilized pivotal, multicenter Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies measured mycological clearance (laboratory confirmation of fungal clearance), clinical clearance (visual resolution of nail symptoms), and the composite endpoint of complete clearance. Findings describe patterns observed in the studies, with research indicating differences in the measured frequency of mycological clearance between the group receiving the study agent and the placebo group. Follow-up data spanning up to four years described the long-term pattern of sustained clearance and monitored recurrence.

What remains uncertain is the full characterization of long-term outcomes beyond the four-year mark. Furthermore, large-scale RCT data that fully establishes outcomes for all pediatric subgroups using the systemic form remains limited. The factors contributing to the variability in the rate of recurrence across different patients are still being explored.


Evidence for Tinea Skin Infections (Athlete's Foot, Ringworm)

Research involving Termider in skin mycoses, specifically Tinea Pedis and Tinea Corporis/Cruris, was evaluated in short-course and comparative trials. These studies examined mycological clearance and monitored clinical response scores that measure symptoms such as scaling, cracking, itching, and burning. Trials described patterns of change in clinical symptom scores that were measured during the study period. Systematic reviews have noted some variability in the definitions used for measuring clinical success across older published trials.

What is still uncertain is the availability of long-term data characterizing recurrence rates, particularly beyond a few months post-treatment. Evidence quality varies across studies, and there is limited information on the optimal treatment duration for the most chronic and extensive forms of the infection.

Key Studies & References

  1. Terbinafine Hydrochloride Tablet Labeling (DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Termider (FAQ)

Q: How long does it typically take to feel any effects from Termider?

A: Relief of clinical symptoms is typically described in official documents as occurring within a few days of starting the medicine. Termider accumulates in the skin and nails; because of this, the active drug substance can persist in these tissues for several weeks, or up to three months, even after the full course of treatment has been completed.

Q: Are there any long-term effects that people commonly ask about with Termider?

A: Studies have examined sustained clearance and recurrence patterns related to fungal infections for up to four years following treatment. For rare, serious safety events like liver injury, official information indicates such conditions often resolve within three to six months after the medication is discontinued. Information regarding long-term effects is available within the full official prescribing documentation.

Q: Does Termider affect birth control pills?

A: Official information indicates that cases of menstrual irregularities and unintended pregnancies have been reported in patients taking oral Termider alongside hormonal contraceptives. The reported rate of this occurrence is generally considered to be within the background incidence for patients taking oral contraceptives alone. Official guidance notes the importance of informing a healthcare provider about all medicines being taken.

Q: Can Termider be taken at the same time as common supplements like vitamins?

A: Regulatory documents mention that certain herbal supplements, such as St. John’s Wort, may interact with Termider by affecting how the body processes the medicine. Regulatory notes highlight the need for a healthcare provider to be informed about all medicines, including vitamins and herbal supplements, being taken.

Q: Is it normal to feel a specific side effect (e.g., drowsiness) when first starting Termider?

A: Drowsiness is not listed by regulatory authorities as a Very Common or Common adverse reaction. Common reactions that may be experienced when starting include headache, nausea, diarrhea, and abdominal pain. A full list of side effects is available in the official product information.

Q: Are there any specific foods that should be avoided when taking Termider?

A: Official guidance states that oral tablets may be taken either with or without food. If the oral granule formulation is used, instructions specify mixing it only with soft, non-acidic food. Regulatory documents do not specify any common foods that must be avoided entirely.

Q: Is Termider available as a generic version, or just the brand name?

A: Termider is the brand name for the active ingredient Terbinafine Hydrochloride, which is also generally available as a generic medicine, subject to local regulatory approvals and availability.

Q: Do studies show Termider is effective for chronic conditions?

A: Research studying outcomes related to fungal infections, which can be chronic, primarily utilized endpoints like mycological clearance and clinical clearance. Findings describe the measured frequency of these outcomes in clinical studies, with a focus on clearing the fungal fungal pathogen at a cellular level.

Q: Is Termider addictive or habit-forming?

A: Official regulatory documents do not classify Termider as a controlled substance, nor is it described as having addictive or habit-forming potential.

Q: Why are there warnings about driving or operating machinery with Termider?

A: Regulatory safety warnings about activities like driving are linked to potential, though less common, nervous system side effects. These include reactions like dizziness or confusion that may affect a patient's attention, coordination, or judgment.

Q: Is Termider safe for elderly people?

A: Geriatric patients are generally eligible for the medicine according to regulatory information. However, caution is advised due to the potential for underlying age-related decline in organ function, particularly concerning the kidney or liver.

Q: Are there any known interactions between Termider and common cold medicines?

A: Yes, Termider is documented to interact with certain components often found in cold medicines. These include the cough suppressant dextromethorphan or sympathomimetic agents (decongestants), which may be associated with an increased concentration of the co-administered cold medicine in the body.

Q: What is the difference between major and minor side effects of Termider?

A: Regulatory documents classify side effects based on both frequency (Very Common, Common) and clinical significance. Serious safety events (often called major) are those that may be life-threatening or result in disability. Less severe reactions are generally considered minor.

Q: Does Termider cause weight gain or weight loss?

A: Changes in body weight, such as weight gain or weight loss, are not listed by regulatory authorities as Very Common or Common adverse reactions for Termider.

Q: Can Termider change the results of certain lab tests?

A: Yes, Termider is known to cause changes in liver enzyme levels, such as serum transaminases (ALT and AST). Official guidance indicates the need for pre-treatment measurement and monitoring of these liver tests during the course of therapy.

Q: Is Termider approved for use in children?

A: The safety and efficacy of the oral tablets for fungal nail infection have not been established in children. However, the oral granule formulation is established for use in children four years of age and older for certain conditions, with dosing tailored to body weight.

Q: What is the shelf life of Termider, and how is that decided?

A: The official product information specifies storage conditions, such as keeping tablets protected from light and moisture. For the topical cream, the label states it must be used within 28 days after first opening. The official shelf life of the sealed product is determined by stability testing performed by the manufacturer.

Q: Does Termider interact with alcohol, even in small amounts?

A: A minor interaction between Termider and alcohol is documented in regulatory interaction summaries. Regulatory summaries indicate the importance of discussing any consumption of alcohol with a healthcare provider.

Q: How quickly does Termider leave the body after stopping it?

A: The elimination half-life is approximately 36 hours, meaning the active substance is mostly cleared from the bloodstream within about a week. However, the medicine remains stored in the skin, nails, and fatty tissues for several weeks to up to three months, continuing its action in these areas.

Q: What percentage of people report experiencing the most common side effects of Termider?

A: Regulatory authorities classify the most frequently documented events, such as gastrointestinal issues, as Very Common. This means they occur in ge 1 out of 10 patients (10% or more) in clinical trials. Specific percentages for each individual event are available in the full prescribing information.

Q: Is there a certain time of day that Termider is usually recommended to be taken?

A: The official guidance is to take the tablets once daily and preferably at the same time each day to help maintain consistent drug levels. There is no requirement in the prescribing information to take the medicine in the morning or the evening.

Q: What kind of studies were done to get Termider approved by the FDA?

A: The regulatory approval was supported by clinical development programs. These included pivotal, multicenter Randomized Controlled Trials (RCTs) and systematic reviews, which evaluated efficacy endpoints such as mycological clearance.

Q: Does Termider come with a medication guide or patient leaflet?

A: Yes, regulatory requirements mandate that a document containing Patient Medication Information or a Patient Leaflet, which summarizes key usage and safety facts, is provided to the patient along with the product.

Q: Can Termider be crushed or mixed with food?

A: Official administration instructions for the oral granule form specify mixing it with soft, non-acidic food and swallowing it unchewed. Oral tablets are typically swallowed whole with water, and crushing the tablets is not part of the standard regulatory instructions.

Q: How does Termider interact with herbal remedies like St. John's Wort?

A: Regulatory documents state that herbal medicines, such as St. John's Wort (Hypericum perforatum), can potentially interact by affecting how the body metabolizes Termider. This interaction could be associated with a reduction in the concentration of Termider in the body, potentially lowering its effectiveness.

Q: Are headaches a common concern when starting Termider?

A: Yes, headaches are classified by regulatory authorities as a Common adverse reaction. This means they are reported in 1 to 10 out of every 100 patients (1%-10%) in clinical studies. This reaction is documented in the safety profile alongside other common effects like GI upset.

Q: If Termider is stopped suddenly, are there any expected effects?

A: Stopping the medicine too soon carries the risk of the symptoms and the underlying fungal infection recurring. Official labeling advises discontinuation and contacting a healthcare provider if taste or smell disorders or symptoms related to depression are experienced.

Q: What is the risk of an allergic reaction to Termider?

A: A history of allergic reaction or hypersensitivity to the drug is an absolute contraindication, meaning the medicine must not be used. Very rare, but serious, effects have been reported, including severe allergic reactions (e.g., anaphylaxis), expected to affect less than 1 in 10,000 patients.

Q: Is Termider known to cause problems with sleep?

A: Sleep disturbances or insomnia are not listed by regulatory authorities as Very Common or Common adverse reactions for Termider.

Q: How do researchers measure the success of Termider in clinical trials?

A: Researchers measure success using specific efficacy endpoints defined by regulatory standards. These typically include mycological clearance (lab confirmation that the fungus is gone), clinical clearance (visual resolution of symptoms), and a composite endpoint of complete clearance.

Q: What does it mean if Termider has a 'Black Box Warning'?

A: The official FDA label for Termider does not contain a 'Black Box Warning' (the most stringent warning required by the FDA). However, the label does include serious warnings about potential rare, but significant, risks to the liver (hepatic dysfunction) and blood and lymphatic system.

How should Termider be stored and disposed of?

The official regulatory requirements for storing and disposing of Termider (Terbinafine) differ slightly by formulation.

Requirement Oral Tablets Topical Cream
Temperature Store at 20 C to 25 C (68 F to 77 F) [1.5]. Store at Controlled Room Temperature; Do not freeze [1.6, 1.4].
Protection Protect from light and excess moisture [1.1]. Protect from light; keep the tube tightly closed [1.4].
Container Keep in the original container, tightly closed [1.1]. Use within 28 days after first opening [1.4].

All forms of this medicine must be kept out of the sight and reach of children [1.1]. For disposal of unused or expired product, the drug is not on the FDA Flush List [2.1]. The recommended method is to use a drug take-back program or discard the medicine in the household trash after mixing it with an unappealing substance, such as dirt or used coffee grounds, and placing it in a sealed container [2.4, 2.7].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Termider found in:

A-Z Index: